Trond Williksen, CEO, commented:
I am pleased to say that we are performing in line with market expectations for the full year, with building momentum in our commercial, operating and financial performance in all business areas. The positive market environment in our core species, our leading market positions, together with our focused strategy and financial discipline positions the Group well to reach profitability and deliver growth.
We are reporting a 38% annual growth in revenue and 145% increase in Adjusted EBITDA. This reflects an excellent performance in Advanced Nutrition, continued good performance in Genetics and the benefit of revenues from the recently launched Ectosan ®Vet and CleanTreat® in Health.
You can read our full financial announcement here
Trond Williksen
